MDXG Mimedx Group Inc
Price (delayed)
$6.15
Market cap
$902.88M
P/E Ratio
9.61
Dividend/share
N/A
EPS
$0.64
Enterprise value
$853.09M
MiMedx is an industry leader in utilizing birth tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare.
Highlights
The debt has plunged by 61% YoY
Mimedx Group's EPS has increased by 23% QoQ
Key stats
What are the main financial stats of MDXG
Market
Valuations
Earnings
Shares outstanding
146.81M
Market cap
$902.88M
Enterprise value
$853.09M
Price to book (P/B)
5.4
Price to sales (P/S)
2.66
EV/EBIT
12.47
EV/EBITDA
11.65
EV/Sales
2.51
Revenue
$340.46M
EBIT
$68.43M
EBITDA
$73.22M
Free cash flow
$48.54M
Per share
Balance sheet
Liquidity
EPS
$0.64
Free cash flow per share
$0.33
Book value per share
$1.14
Revenue per share
$2.31
TBVPS
$1.35
Total assets
$230.18M
Total liabilities
$62.14M
Debt
$19.25M
Equity
$168.04M
Working capital
$114.01M
Debt to equity
0.11
Current ratio
3.85
Quick ratio
3.04
Net debt/EBITDA
-0.68
Margins
Efficiency
Dividend
EBITDA margin
21.5%
Gross margin
83.4%
Net margin
27.1%
Operating margin
21.7%
Return on assets
42%
Return on equity
78.9%
Return on invested capital
60.7%
Return on capital employed
36%
Return on sales
20.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MDXG stock price
How has the Mimedx Group stock price performed over time
Intraday
-0.65%
1 week
-3.61%
1 month
-1.76%
1 year
-22.64%
YTD
-29.87%
QTD
-11.26%
Financial performance
How have Mimedx Group's revenue and profit performed over time
Revenue
$340.46M
Gross profit
$283.99M
Operating income
$74.02M
Net income
$92.31M
Gross margin
83.4%
Net margin
27.1%
MDXG's net income is up by 22% QoQ
The operating income rose by 20% QoQ
The net margin has grown by 19% from the previous quarter
The operating margin has grown by 18% from the previous quarter
Growth
What is Mimedx Group's growth rate over time
Valuation
What is Mimedx Group stock price valuation
P/E
9.61
P/B
5.4
P/S
2.66
EV/EBIT
12.47
EV/EBITDA
11.65
EV/Sales
2.51
Mimedx Group's EPS has increased by 23% QoQ
The P/B is 97% lower than the last 4 quarters average of 164.2
Mimedx Group's equity has increased by 8% QoQ
MDXG's revenue is up by 15% YoY
The P/S is 14% lower than the last 4 quarters average of 3.1 but 3.1% higher than the 5-year quarterly average of 2.6
Efficiency
How efficient is Mimedx Group business performance
Mimedx Group's return on sales has increased by 41% QoQ
MDXG's return on invested capital is up by 36% since the previous quarter
Mimedx Group's return on equity has decreased by 25% QoQ
MDXG's ROA is up by 14% QoQ
Dividends
What is MDXG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MDXG.
Financial health
How did Mimedx Group financials performed over time
The total liabilities has contracted by 36% YoY and by 6% from the previous quarter
The total assets has grown by 31% YoY and by 3.8% from the previous quarter
The debt is 89% less than the equity
MDXG's debt to equity has soared by 103% year-on-year but it is down by 8% since the previous quarter
The debt has plunged by 61% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.